Short answer: Foundayo (orforglipron) is a new once-daily oral GLP-1 pill approved in April 2026 — and unlike Wegovy's oral tablet or Rybelsus, it can be taken any time of day with no food or water restrictions.[1]It's chemically different from both semaglutide and tirzepatide. At the commercial maximum of 17.2 mg once daily, labeled Trial 1 showed about −11.1% average weight loss versus −2.1% placebo at 72 weeks — meaningful, but behind high-dose oral Wegovy's OASIS-4 results and the top injectables.[2][3] Separately, orforglipron outperformed oral semaglutide 14 mg in diabetes-dose head-to-heads (ACHIEVE-3); that is not a like-for-like obesity comparison with oral Wegovy 25 mg.[6]
If you've been comparing semaglutide and tirzepatide and just started seeing Foundayo mentioned alongside them, here's what actually separates it — the mechanism, the dosing, the trial data, and the cost.
Key Takeaways
- Foundayo (orforglipron) is a new once-daily oral GLP-1 pill, FDA-approved April 2026 — no food or water restrictions, unlike other oral GLP-1s
- At the commercial maximum dose (17.2 mg), trial data showed ~11.1% average weight loss vs. 2.1% placebo — meaningful, but behind high-dose oral Wegovy and the top injectables
- Self-pay pricing ranges $149–$349/month depending on dose; commercially insured patients may pay as little as $25/month
- Foundayo's biggest advantage is convenience, not maximum weight loss
This article is fact-checked against FDA prescribing information, peer-reviewed clinical trials (NEJM, The Lancet), and manufacturer labeling. Last updated September 16, 2026. Full sources listed below.
Jump to section
What Makes Foundayo Different
Semaglutide (Wegovy, Ozempic, Rybelsus) and tirzepatide (Zepbound, Mounjaro) are both peptide-based medications — larger molecules that, in their oral forms, need to be taken under specific conditions (empty stomach, limited water, timed before food) so the body can absorb them intact.[7]
For a closer look at Foundayo's chemistry and full trial data, see our dedicated Foundayo explainer.
Foundayo (orforglipron) is a small molecule — a fundamentally different type of chemistry that doesn't require those same absorption workarounds. That's why Lilly can say it's taken any time of day, without food or water restrictions, a real practical difference from oral Wegovy and Rybelsus, which both require empty-stomach, limited-water dosing.[2][7]
Mechanistically, Foundayo is a GLP-1 receptor agonist — like semaglutide, it activates the GLP-1 receptor. It does not activate the second GIP receptor that tirzepatide does, so in terms of mechanism, it sits closer to semaglutide than tirzepatide, just built on different underlying chemistry.[2]
Not sure if Foundayo is right for you?
Take our free 2-minute quiz to see which GLP-1 option fits your health history, goals, and budget.
Find My Best Match →2 minutes. No email required.
Brand Names and Formulations
Foundayo has one brand name and one form so far — there's no injectable version and no diabetes-specific formulation yet, unlike semaglutide and tirzepatide, which each split across a weight-loss brand and a diabetes brand.
- Foundayo — oral tablet, once daily, FDA-approved April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Approved strengths span 0.8 mg through 17.2 mg; the maximum recommended dose is 17.2 mg once daily.[1][2]
For comparison, here's where that fits alongside the semaglutide and tirzepatide options already on the market:
| Medication | Brand | Form | Manufacturer | Approved For |
|---|---|---|---|---|
| Orforglipron | Foundayo | Oral tablet | Eli Lilly | Weight management (2026) |
| Semaglutide | Wegovy | Injectable | Novo Nordisk | Weight management |
| Semaglutide | Wegovy (oral) | Oral tablet | Novo Nordisk | Weight management (2025) |
| Semaglutide | Ozempic | Injectable | Novo Nordisk | Type 2 diabetes |
| Semaglutide | Rybelsus | Oral tablet | Novo Nordisk | Type 2 diabetes |
| Tirzepatide | Zepbound | Injectable | Eli Lilly | Weight management |
| Tirzepatide | Mounjaro | Injectable | Eli Lilly | Type 2 diabetes |
What the Clinical Trial Data Shows
Foundayo's labeled Trial 1 result at the commercial maximum of 17.2 mg once daily was about −11.1% versus −2.1% placebo at 72 weeks — clinically meaningful, but behind high-dose oral Wegovy in OASIS-4 and the top injectable options.[2][3]
| Medication | Trial Context | Avg. Weight Loss |
|---|---|---|
| Foundayo (orforglipron), 17.2 mg | Trial 1 (label), 72 weeks | −11.1% vs −2.1% placebo |
| Oral Wegovy (25 mg) | OASIS-4, 64 weeks | −13.6% vs −2.2% placebo (treatment-policy); −16.6% on-treatment |
| Wegovy HD (7.2 mg injectable) | Phase 3, 72 weeks | ~20.7% |
| Zepbound (highest dose) | SURMOUNT-1 | Up to 20.9% |
OASIS-4's primary treatment-policy estimand was −13.6% versus −2.2% placebo at week 64; the often-quoted −16.6% figure is the on-treatment / hypothetical estimand — not the primary analysis.[4] SURMOUNT-1 reported up to 20.9% average weight loss with tirzepatide 15 mg at 72 weeks.[5]
In ACHIEVE-3, a type 2 diabetes head-to-head, orforglipron at higher development doses produced greater relative weight loss than oral semaglutide 14 mg. That comparison is directional for diabetes dosing — it is not a like-for-like obesity ranking of commercial Foundayo 17.2 mg against oral Wegovy 25 mg.[6]
The takeaway: if you're choosing purely by average trial weight loss, the highest-dose injectables (Wegovy HD, Zepbound) still lead, and high-dose oral Wegovy also outranks labeled Foundayo Trial 1 results. Foundayo's advantage is convenience — no injections, no food/water timing rules — not maximum average weight loss.[2][4][5]
Side Effects
Foundayo's most common side effects in trials were gastrointestinal — nausea, diarrhea, vomiting, indigestion, and decreased appetite — the same general side-effect category shared by semaglutide and tirzepatide. Like both of those medications, Foundayo carries the same class-wide boxed warning for thyroid C-cell tumors seen in animal studies, and the same contraindication for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.[2][3]
Dosing
Foundayo is taken once daily, starting at a low 0.8 mg dose and titrating upward through several dose tiers (2.5 mg, 5.5 mg, 9 mg, 14.5 mg, up to 17.2 mg) as tolerated — a stepwise approach similar in spirit to how Wegovy and Zepbound are titrated, though the specific schedule differs. The maximum recommended dose is 17.2 mg once daily. The exact pace of any dose increase is something a prescriber manages individually.[2][3]
Cost
Foundayo's pricing is tiered by dose, not a single flat number:
| Access Path | Price | Where to Start |
|---|---|---|
| Self-pay, starter dose (0.8 mg) | $149/month | See Pricing → |
| Self-pay, mid-range doses | $199–$299/month | See Pricing → |
| Self-pay, highest doses (14.5–17.2 mg) | $349/month | See Pricing → |
| Eligible commercial insurance (with savings card) | As low as $25/month | See Pricing → |
| Eligible Medicare GLP-1 Bridge (starting July 1, 2026) | As low as $50/month | See Pricing → |
At launch, Foundayo is available primarily through Eli Lilly's direct-to-consumer platform, LillyDirect, with broader retail pharmacy and telehealth availability expanding afterward. Because it only just launched, expect pricing and access to keep evolving over the next several months — worth checking current terms directly before assuming any number here is still exact.
Real-time pricing across oral GLP-1 providers
So Which One Is Right for You?
This isn't something RENVA can answer for you — that's a conversation for you and a licensed prescriber, who can weigh your health history, tolerance for injections versus pills, insurance coverage, and cost. What the data can tell you is this: Foundayo offers a genuinely different convenience profile — no injections, no food or water timing rules — while the highest-dose injectable options still lead on average trial weight loss. None of these medications work as a short-term fix; all require sustained use to maintain results.
Not ready to decide?
Get our free GLP-1 comparison guide and price-drop alerts sent to your inbox.
No spam. Unsubscribe anytime.
Sources
- FDA Approves First New Molecular Entity Under National Priority Voucher Program (Foundayo) — U.S. Food and Drug Administration fda.gov
- FOUNDAYO (orforglipron) — Prescribing Information — U.S. Food and Drug Administration accessdata.fda.gov
- FOUNDAYO (orforglipron) — DailyMed — NLM DailyMed dailymed.nlm.nih.gov
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4) — New England Journal of Medicine nejm.org
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine nejm.org
- Orforglipron vs oral semaglutide in type 2 diabetes (ACHIEVE-3) — The Lancet thelancet.com
- WEGOVY (semaglutide) tablets — Prescribing Information — U.S. Food and Drug Administration accessdata.fda.gov
Frequently Asked Questions
Q: Is Foundayo the same as semaglutide or tirzepatide?
No. Foundayo (orforglipron) is a different type of medication chemically — a small molecule rather than a peptide — though it works through a similar GLP-1 mechanism to semaglutide.
Q: Why can Foundayo be taken without food or water restrictions when other oral GLP-1s can't?
It comes down to chemistry. Foundayo's small-molecule structure doesn't require the same absorption conditions that oral semaglutide (Wegovy pill, Rybelsus) needs to work properly.
Q: Is Foundayo more effective than Wegovy or Zepbound?
Based on labeled Trial 1 data, Foundayo at the commercial max of 17.2 mg (−11.1% vs −2.1% placebo at 72 weeks) trails high-dose oral Wegovy in OASIS-4 and the top injectable doses of Wegovy HD and Zepbound. Separately, orforglipron outperformed oral semaglutide 14 mg in the ACHIEVE-3 diabetes head-to-head at development doses — that is not a like-for-like obesity comparison with oral Wegovy 25 mg.
Q: How much does Foundayo cost?
Self-pay pricing starts at $149/month for the starter dose and scales up to $349/month at the highest doses, through Eli Lilly's LillyDirect platform. Eligible commercially insured patients may pay as little as $25/month with a savings card.
Q: Can I switch from Wegovy or Zepbound to Foundayo?
That's a decision for you and a licensed prescriber — switching between GLP-1 medications involves dosing considerations that should be individually managed.
For a full breakdown of semaglutide vs. tirzepatide specifically, see Semaglutide vs. Tirzepatide: What's the Difference?.